

Low prevalence of HIV and other selected sexually transmitted infections in 2004 in pregnant women from Kinshasa, the Democratic Republic of the Congo

R. KINOSHITA-MOLEKA^{1,2}, J. S. SMITH^{1*}, J. ATIBU², A. TSHEFU³,
J. HEMINGWAY-FODAY⁴, M. HOBBS⁵, J. BARTZ⁴, M. A. KOCH⁴,
A. W. RIMOIN^{6,7} AND R. W. RYDER^{1,5}

¹ Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

² UNC/DRC Program, Kinshasa, Democratic Republic of the Congo

³ Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo

⁴ RTI international, Research Triangle Park, NC, USA

⁵ School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

⁶ National Institutes of Health (NIH), Bethesda, Maryland, USA

⁷ Department of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, California, USA

(Accepted 26 September 2007; first published online 21 November 2007)

SUMMARY

This study examined the prevalence of HIV and other sexually transmitted infections (STIs) in pregnant women in Kinshasa, the Democratic Republic of the Congo (DRC). Between April and July 2004, antenatal attendees at two of the largest maternity clinics in Kinshasa were tested to identify HIV status, syphilis, *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG). HIV seroprevalence was 1·9% in 2082 women. With PCR techniques, CT and NG infections were also uncommon in the first 529 women (1·7% and 0·4%, respectively). No active syphilis infection case was identified by Treponema pallidum haemagglutination assay (TPHA) and rapid plasma reagin test (RPR). A woman's risk of HIV infection was significantly associated with her reporting a male partner having had other female sexual partners (OR 2·7, 95% CI 1·2–6·2). The continuing low seroprevalence of HIV in pregnant women from Kinshasa was confirmed. Understanding factors associated with this phenomenon could help prevent a future HIV epidemic in low HIV transmission areas in Africa.

INTRODUCTION

About 25·8 million HIV-seropositive individuals live in sub-Saharan Africa, representing two thirds of the world's total HIV burden [1]. HIV and other sexually transmitted infections (STIs) are the second most common cause of healthy life years lost in women

aged 15–44 years in Africa, and account for 17% of the total disease burden in this population [2]. Despite the notable endemicity of HIV in sub-Saharan Africa, HIV seroprevalence in pregnant women differs markedly across this region, ranging from a low of 1% in Senegal and Mauritania to a high of 39% in Swaziland [3].

Time trends of HIV seropositivity in pregnant women have been used to monitor the HIV epidemic at the population level [4]. Although little data are available on HIV seroprevalence in many Central

* Author for correspondence: Dr J. S. Smith, Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, NC, USA.
(Email: jennifers@unc.edu)

African countries, HIV seroprevalence data in the Democratic Republic of the Congo (DRC) have been documented since 1984 by the National AIDS Control Programme and Project SIDA, the first international HIV/AIDS programme in sub-Saharan Africa. Taken together, HIV prevalence in pregnant women in the DRC has consistently remained at <10% [5–8]. Most recently, HIV prevalence in pregnant women in the capital city Kinshasa has been stable, no more than 5% between 2000–2004 [9–12]. Data in 2002 for 1267 pregnant women from four major cities in the DRC reported a HIV-1 seropositivity of 3.5% [11]. Official sentinel survey data for 2003–2004 showed that the HIV-1 seroprevalence in pregnant women in the DRC was 4.5% [12].

In this report, we document the prevalence and associated risk factors of HIV infection and selected STIs in a large representative sample of pregnant women from two major maternity clinics in Kinshasa in 2004.

METHODS

Between April and July 2004, 2138 consecutive antenatal clinic attendees at the Kingasani and Binza maternity clinics in Kinshasa, DRC were invited to participate in a prevalence survey of HIV and selected STIs in order to plan future studies of infection control in pregnant women. Inclusion criteria for participation were: >15 years of age, agreement to participate in HIV testing, and receipt of no previous antenatal care (ANC) during their current pregnancy. A total of 2134 women (99.8%) were eligible and 33 women (1.6%) declined to participate. Informed consent was obtained from each participant, including parental consent from participating minors. All 2101 consenting participants underwent HIV testing, provided a 5 ml blood specimen, and were individually interviewed by trained female nurses on sociodemographic information, previous pregnancy history, and sexual behaviour. In this study, for history of previous birth outcomes, we defined neonatal, infant, and child deaths as deaths <1 month of birth, deaths between 1 month and 1 year of birth, and deaths >1 year of birth, respectively. Limited resources enabled the provision of STI screening for only the first consenting 529 women. Among these women, vaginal swab samples (Starswab II with liquid Stuart's medium, Starplex Scientific, Entbicoke, ON, Canada) were successfully collected by trained female nurses from

524 women at the time of a speculum pelvic examination.

Blood samples were transported on a daily basis to the National AIDS Reference Laboratory in Kinshasa where plasma was separated and then frozen at -20°C . The frozen blood plasma samples were tested for HIV and syphilis within 48 h. HIV-1/-2 serostatus was first tested using two different enzyme-linked immunosorbent assays (ELISAs): Vironostika[®] HIV Uni-Form II Plus 0 (bioMérieux, Boxtel, The Netherlands) and Enzygnost[®] Anti-HIV 1/2 Plus (Dade Behring, Marburg, Germany). If both tests were positive, HIV seropositivity was confirmed with a rapid test assay (Determine HIV-1/-2; Abbott Laboratory, Tokyo, Japan). All women with two positive ELISAs and a positive rapid test result were classified as being HIV positive. Eleven women with indeterminate HIV results (0.5%) and eight with missing samples were excluded from data analyses, leaving a total of 2082 women.

Using residual blood specimens, syphilis seropositivity was determined by a rapid plasma reagin test (RPR: Human GmbH, Wiesbaden, Germany) and a *Treponema pallidum* haemagglutination assay (TPHA: Serodia[®]-TP-PA; Fujirebio Inc., Tokyo, Japan) with 525 women. Samples testing positive for RPR or TPHA and 2% of randomly selected negative samples were shipped to the laboratory at the University of North Carolina at Chapel Hill (UNC-CH) for quality control.

Vaginal swab samples were tested for *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) DNA using an amplicor polymerase chain reaction-based assay (PCR, Roche Diagnostics, Indianapolis, IN, USA) at the UNC-CH microbiology laboratory. All positive samples were systematically re-tested for confirmatory purposes. To monitor the adequacy of specimen storage and transport conditions, a vial of Accurun 341 external positive control (BBI Diagnostics, West Bridgewater, MA, USA) containing CT and NG intact organisms was stored and included with each batch of specimens shipped from Kinshasa to UNC-CH. All vials tested positive in the Amplicor CT/NG assay, confirming that specimen storage and transport conditions had been adequate.

To identify risk factors for HIV seropositivity, odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated using multivariate logistic regression adjusting for maternal age [13, 14] and site of ANC. For sparse data (cell counts with sample

Table 1. Prevalence of HIV and selected sexually transmitted infections in female antenatal clinic attendees at two maternity clinics in Kinshasa, Democratic Republic of the Congo

	No. tested*	Positive n (%)
HIV	2082	40 (1.9)
Syphilis		
Past/treated infection†	525	12 (2.3)
Active infection‡	525	0 (0.0)
<i>Chlamydia trachomatis</i>	521	9 (1.7)
<i>Neisseria gonorrhoeae</i>	521	2 (0.4)

* Numbers may differ due to missing samples and refusals.

† Defined as *Treponema pallidum* haemagglutination assay (TPHA) positive and rapid plasma reagin test (RPR) negative.

‡ Defined as TPHA and RPR positive.

size ≤ 5), exact logistic regression was performed using LogXact 4 for Windows (Cytel Software Corporation, Cambridge, MA, USA).

The protocol was approved by the Institutional Review Boards at UNC-CH, RTI International, and the Kinshasa School of Public Health.

RESULTS

We detected a HIV prevalence rate of 1.9% (95% CI 1.3–2.5) in the 2082 participating pregnant women whose mean age was 27.3 years (range 15–45 years) (Table 1). HIV seropositivity was low in women from both antenatal clinics (1.6% in Kingasani and 2.2% in Binza, $P=0.33$), and in the first 529 women who consented to have STI testing (1.5%) (data not shown). No active syphilis case was detected in 525 women. Three samples (0.6%) were RPR positive but TPHA negative, suggesting false-positive results. External quality control of the syphilis test performed at the UNC-CH laboratory confirmed these results. CT and NG infection prevalence rates were 1.7% and 0.4%, respectively in 521 women. None of the patients were found to have more than one STI.

No significant association was found between women's age and HIV prevalence (Table 2). Women aged between 25 and 29 years had a slightly higher HIV risk, with the lowest prevalence in the youngest and the oldest women, although these differences were not statistically significant. A woman's HIV risk was significantly associated with her reporting a male partner as having had other female sexual partners

(OR 2.7, 95% CI 1.2–6.2), although only a small proportion of women (10.4%) reported this behaviour. A pregnant woman's reported history of previous neonatal deaths was not related to her risk of HIV infection; however, a history of previous infant (OR 2.5, 95% CI 1.1–5.6) and child (OR 2.7, 95% CI 1.2–5.9) deaths were positively associated with HIV infection. When the statistically significant factors were modelled simultaneously, a woman's report of a male partner having ever had other female sexual partner(s), infant deaths, and child deaths remained significant.

DISCUSSION

This study confirms the continuing paradoxically low HIV seroprevalence in Kinshasa, DRC, a location where many of the factors found to enable HIV infection in other regions of sub-Saharan Africa are highly prevalent [7, 8]. These enablers include political and social instability, widespread poverty, long-lasting conflicts in the Eastern parts of the country, commercial sex and lack of access to effective testing and treatment of STIs. Despite these highly prevalent enabling conditions, the persistently stable and low HIV prevalence rates remain a striking and unexplained phenomenon.

The HIV prevalence rate in our study participants (1.9%) was consistent with the results from the Global AIDS Programme in Kinshasa that documented a 1.9% HIV-1 seroprevalence in 38 603 pregnant women surveyed at 21 maternity clinics (excluding Kingasani and Binza clinics) from 2004 to July 2005 (F. Behets, personal communication). The cumulative HIV prevalence at the Kingasani and Binza maternity clinics from 2003 to 2005 was 2.4% among 37 988 pregnant women (R. Matendo, personal communication). Similarly low HIV seroprevalence rates were reported in pregnant women in neighbouring countries in 2001–2002 including Angola (2%) and the Republic of the Congo (4%) [3], although high HIV prevalence rates have been reported in nearby Zambia (23.5%) [10] and the Central African Republic (CAR; 15%) [3].

Our study provides new data on the burden of selected STIs (CT and NG) in pregnant women from the DRC using sensitive PCR-based laboratory testing. Antenatal attendees from the two largest maternity clinics in Kinshasa had a low prevalence of both infections (1.7% and 0.4%, respectively). A previous study in Kinshasa [15] found a higher prevalence of CT (5.2%) and NG (1.6%) infections in

Table 2. Risk factors for HIV infection in 2082 female antenatal clinic attendees at two maternity clinics in Kinshasa, Democratic Republic of the Congo

	No. tested (<i>n</i> = 2082)	HIV positive (<i>n</i> = 40) <i>n</i> (%)	Adjusted OR* (95% CI)
Site of maternity clinics			
Binza	1039	23 (2.2)	1.3 (0.7–2.5)
Kingasani	1043	17 (1.6)	1†
Sociodemographic characteristics			
Age (years)§			
<20	213	2 (0.9)	0.9 (0.1–8.4)
20–24	538	8 (1.5)	1.5 (0.3–8.7)
25–29	609	18 (3.0)	2.9 (0.8–15.5)
30–34	437	9 (2.1)	2.0 (0.5–11.4)
≥35	285	3 (1.1)	1†
<i>P</i> value for linear trend			0.83
<i>P</i> value (2 D.F.) for quadratic trend			0.19
Marital status§			
Married	1754	35 (2.0)	1†
Cohabiting	288	3 (1.0)	0.7 (0.1–2.5)
Single	37	2 (5.4)	4.0 (0.4–19.4)
Sexual behaviour			
Woman reports male sexual partner has had other female partner(s)			
Never	1479	22 (1.5)	1†
Ever	216	8 (3.7)	2.7 (1.2–6.2)‡
Unsure	383	10 (2.6)	1.9 (0.9–4.0)
More than one sexual partner 3 months prior to the pregnancy§			
No	2056	39 (1.9)	1†
Yes	23	1 (4.4)	2.8 (0.1–19.2)
Previous obstetric/birth outcomes			
Live children			
0	563	9 (1.6)	1†
1	446	12 (2.7)	1.3 (0.5–3.3)
2–3	627	13 (2.1)	0.9 (0.3–2.3)
≥4	446	6 (1.4)	0.7 (0.2–2.4)
<i>P</i> value for linear trend			0.26
History of infant/child deaths			
Neonatal deaths (<1 month of birth)§			
Never	1955	38 (1.9)	1†
Ever	127	2 (1.6)	0.8 (0.1–3.2)
Infant deaths (1 month to 1 year of birth)			
Never	1885	32 (1.7)	1†
Ever	197	8 (4.1)	2.5 (1.1–5.6)‡
Child deaths (>1 year of birth)			
Never	1850	31 (1.7)	1†
Ever	232	9 (3.9)	2.7 (1.2–5.9)‡

CI, Confidence interval; OR, odds ratio.

* Adjusted for age and site of antenatal clinic.

† Reference category.

‡ *P* < 0.05.

§ Data analysed by exact logistic regression.

|| Standard logistic regression result.

1160 pregnant women using an enzyme immunoassay and cultured endocervical smears, respectively. The low prevalence of cervical infections found in our present study appears to be real, given the higher sensitivity of the PCR-based laboratory assay used. In our study, no active syphilis was found and only 0.6% of women screened tested RPR positive, TPHA negative. These later results are consistent with the low syphilis prevalence rate of 0.43% by RPR only found in 1619 female antenatal clinic attendees from three maternity clinics in Kinshasa in 2003 [16].

A woman's risk of HIV infection was significantly associated with her reporting a male partner as having had other female sexual partners. These data are consistent with population-based studies from Nigeria showing a higher risk of STIs in women reporting a partner with higher risk sexual behaviour [13, 17]. Given the low HIV seroprevalence reported here, sexual network analyses documenting the extent of partner change and of concurrent sexual partnerships in this population may provide further insights [18].

Civil war, political instability, and widespread poverty in the DRC could have been expected to increase the vulnerability of the population to HIV and other STI infections, yet the prevalences of HIV and selected STIs reported here were low. HIV acquisition and transmission can be facilitated by other STI infections through multiple immunological and biological pathways [19–21]. The low prevalence of selected STIs found here may provide one potential explanation for the stable, low HIV seroprevalence in the DRC relative to other sub-Saharan African countries. Behavioural factors including a high prevalence of male circumcision have been shown to significantly reduce HIV risk [22, 23]. The circumcision rate is estimated to be 80–90% in Congolese males in Kinshasa (B. Lapika, personal communication). The low and stable HIV prevalence in the DRC might also be attributable to high HIV-related mortality that could have maintained the balance between the number of new infections cases and HIV deaths [7]. A better access to quality health care could contribute to prolongation of life in people living with HIV/AIDS, and hence a longer duration of HIV infection in HIV positives and high levels of HIV prevalence in a population [24]. However, in the DRC this is not the case, due to the rapidly deteriorating health service system and lack of access to health care as a consequence of decades of mismanagement and corruption, and extreme poverty [11].

Finally, the extremely high diversity of HIV-1 subtypes found in the DRC may be associated with the relatively slow HIV transmission patterns compared to other sub-Saharan African countries with high prevalence where only one HIV-1 subtype (subtype C) is predominant [25, 26]. As observed in the DRC, the largest variety of HIV-1 subtypes is found in Central Africa where the HIV prevalence has been low except in CAR (15%) and Cameroon (8%) (data for ANC attendees) [3]. Interestingly, subtype E which is primarily responsible for the explosion of the HIV epidemic in the heterosexual population in Thailand, is commonly found in CAR but not in other African countries [26]. Further studies are required to identify biological differences in infectivity, transmissibility, and immunogenicity among these HIV-1 subtypes that may explain trends in HIV seroprevalence in countries such as DRC [27, 28].

Our study results are based on a large sample size and sensitive laboratory PCR techniques for the ascertainment of selected STIs. Furthermore, HIV seroprevalence was determined at two of the largest maternity clinics where 14.2% of the 114 144 deliveries occur in Kinshasa (Office of District Medical Inspection, Kinshasa, DRC). An estimated 85% of pregnant women attend at least one ANC visit during pregnancy in Kinshasa [29].

Nevertheless, our study has certain limitations. Despite the large number of women enrolled in the study, the sample size was too small to examine the association between HIV and other STIs [19–21], due to the low prevalence of both HIV and selected STIs. Selecting only two maternity clinics may not represent the pregnant population from different socio-demographic and geographical areas in Kinshasa. Data on other important behavioural risk factors for HIV and STI infections such as condom use, number of current or lifetime male sexual partners, and the prevalence of sex work in the target population were not available as this was beyond the scope of the study.

The historically stable and low seroprevalence of HIV in pregnant women was confirmed at two of the largest maternity clinics in Kinshasa, DRC. The prevalence rates of CT, NG, and syphilis were also lower than expected in this population. Understanding the factors contributing to the low and stable HIV prevalence in the DRC, including further analyses of the balance between HIV/AIDS deaths and newly infected cases, patterns of sexual behaviours, and the prevalence of other STIs such as herpes simplex

virus 2 (HSV-2) are important to prevent the possible future expansion of an HIV epidemic in the low HIV transmission areas in Africa.

ACKNOWLEDGEMENTS

The authors acknowledge K. Rich (UNC-CH Microbiology Laboratory) and S. Edidi (DRC National AIDS Reference Laboratory) for laboratory technical support. G. Mpanya, M. Onyamboko, and K. Mwandagalirwa worked in the planning and implementation phases of the study. This work was financed by the Global Network for Women's and Children's Health Research (NICHD U01 HD043475-01) and the Bill & Melinda Gates Foundation. J. Smith was supported through a Center for AIDS Research grant (5 P30 AI050410-07 NIAID). Logistical support for STI testing was provided by the North Carolina STI and Topical Microbicide Cooperative Research Center grant (5 U19 AI031496-14).

DECLARATION OF INTEREST

None.

REFERENCES

1. **UNAIDS/WHO.** AIDS Epidemic Updates December 2005. (http://www.unaids.org/epi/2005/doc/report_pdf.asp). Accessed 25 March 2006.
2. **World Bank.** World Development Report 1993. *Investing Health*. New York: Oxford University Press for the World Bank, June 1993.
3. **Asamoah-Odei E, Garcia Calleja JM, Boerma T.** HIV prevalence and trends in sub-Saharan Africa: no decline and large subregional differences. *Lancet* 2004; **364**: 35–40.
4. **Zaba BW, et al.** Adjusting ante-natal clinic data for improving estimates of HIV prevalence among women in sub-Saharan Africa. *AIDS* 2000; **14**: 2741–2750.
5. **Batter V, et al.** High HIV-1 incidence in young women masked by stable overall seroprevalence among child-bearing women in Kinshasa, Zaïre: estimating incidence from serial seroprevalence data. *AIDS* 1994; **8**: 811–817.
6. **Mertens TE, Low-Beer D.** HIV and AIDS: where is the epidemic going? *Bulletin of the World Health Organization* 1996; **74**: 121–129.
7. **Mulanga-Kabeya C, et al.** Evidence of stable HIV seroprevalences in selected population in the Democratic Republic of the Congo. *AIDS* 1998; **12**: 905–910.
8. **Buvé A, Bishikwabo-Nsarhaza K, Mutangadura G.** The spread and effect of HIV-1 infection in sub-Saharan Africa. *Lancet* 2002; **359**: 2011–2017.
9. **UNAIDS/WHO.** Epidemiological Fact Sheet – Update on HIV and Sexually Transmitted Infections: Democratic Republic of the Congo, 2004 (<http://www.who.int/globalatlas/predefinedReports/EFS2004/index.asp>). Accessed 21 October 2005.
10. **U.S. Bureau of the Census.** HIV/AIDS Surveillance Data Base. Version 9/2004 (<http://www.census.gov/ipc/www/hivaidn.html>). U.S. Bureau of the Census, Washington, DC. Accessed 21 October 2005.
11. **Mulanga C, et al.** Political and socioeconomic instability: how does it affect HIV? A case study in the Democratic Republic of Congo. *AIDS* 2004; **18**: 832–833.
12. **Ministry of Public Health, DRC.** République Démocratique du Congo, Ministère de la Santé Publique, Programme National de Lutte Contre le VIH/SIDA et les ISTs (PNLS). Rapport du Passage de la Surveillance Sentinelle du VIH Chez les Femmes Enceintes Fréquentant les Services de CPN: Mai 2003–Mai 2004. Kinshasa, RDC. June 2004.
13. **Sagay AS, et al.** HIV infection among pregnant women in Nigeria. *International Journal of Gynaecology and Obstetrics* 2005; **90**: 61–67.
14. **Buvé A, et al.** Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. *AIDS* 2002; **16**: 2101–2102.
15. **Vuytsteke B, et al.** Clinical algorithms for the screening of women for gonococcal and chlamydial infection: evaluation of pregnant women and prostitutes in Zaire. *Clinical Infectious Diseases* 1993; **17**: 82–88.
16. **Ministry of Public Health, DRC.** République Démocratique du Congo Ministère de la Santé, Programme National de Lutte Contre le VIH/SIDA et les ISTs (PNLS). Rapport du Passage de la Surveillance Sentinelle du VIH Chez les Femmes Enceintes Fréquentant les Services de CPN: 2003–2004. June 2004.
17. **Thomas JO, et al.** Prevalence of papilloma virus infection in women in Ibadan, Nigeria: a population-based study. *British Journal of Cancer* 2004; **90**: 638–645.
18. **Lagarde E, et al.** Concurrent sexual partnerships and HIV prevalence in five urban communities of sub-Saharan Africa. *AIDS* 2001; **15**: 877–884.
19. **Cohen MS.** HIV and sexually transmitted diseases: lethal synergy. *Topical HIV Medicine* 2004; **12**: 104–107.
20. **Sangai P, Rutherford G, Wilkinson D.** Population-based interventions for reducing sexually transmitted infections, including HIV infection. *The Cochrane Database of Systematic Reviews* 2004. Issue 2. Article No: CD001220.
21. **Cohen MS.** Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. *Lancet* 1998; **351** (Suppl. 3): 5–7.
22. **Weiss HA, Quigley MA, Hayes RJ.** Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. *AIDS* 2000; **14**: 2361–2370.
23. **Anon.** International AIDS Society conference update. Male circumcision as a prevention method? Study was

- controversial from day one. *AIDS Alert* 2005; **20**: 101–102.
24. **Boerma JT, et al.** Understanding the uneven spread of HIV within Africa: Comparative study of biologic, behavioral, and contextual factors in rural populations in Tanzania and Zimbabwe. *Sexually Transmitted Diseases* 2003; **30**: 779–787.
 25. **Vidal N, et al.** Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. *Journal of Acquired Immune Deficiency Syndrome* 2005; **40**: 456–462.
 26. **Janssens W, Buvé A, Nkengasong JN.** The puzzle of HIV-1 subtypes in Africa. *AIDS* 1997; **11**: 705–712.
 27. **Geretti AM.** HIV-1 subtypes: epidemiology and significance for HIV management. *Current Opinion in Infectious Diseases* 2006; **19**: 1–7.
 28. **Vidal N, et al.** Identification and molecular characterization of subsubtype A4 in Central Africa. *AIDS Research and Human Retroviruses* 2006; **22**: 182–187.
 29. **République Démocratique du Congo, UNICEF, USAID.** Enquête nationale sur la situation des enfants et des femmes. MICS2/2001, Volume II. Rapport d'analyse. Kinshasa, DRC; 2002, p. 87.